Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03980483
Registration number
NCT03980483
Ethics application status
Date submitted
15/05/2019
Date registered
10/06/2019
Date last updated
25/10/2023
Titles & IDs
Public title
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Query!
Scientific title
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Query!
Secondary ID [1]
0
0
201790
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
contRAst 1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - GSK3196165 (Otilimab)
Treatment: Drugs - Tofacitinib 5 mg
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Experimental: GSK3196165 90mg + MTX - Participants received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with methotrexate (MTX).
Experimental: GSK3196165 150mg + MTX - Participants received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with MTX.
Active Comparator: Tofacitinib 5mg + MTX - Participants received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with MTX plus placebo injection weekly to maintain the blind for 52 weeks.
Placebo Comparator: Placebo + MTX and GSK3196165 90mg + MTX - Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with MTX until Week 52.
Placebo Comparator: Placebo + MTX and GSK3196165 150mg + MTX - Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with MTX until Week 52.
Placebo Comparator: Placebo + MTX and Tofacitinib 5mg + MTX - Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.
Other interventions: GSK3196165 (Otilimab)
GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Treatment: Drugs: Tofacitinib 5 mg
Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
Treatment: Drugs: Placebo
Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
Treatment: Drugs: Placebo
Placebo cap (containing lactose) to be administered orally.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo
Query!
Assessment method [1]
0
0
ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) [visual analogue scale (VAS) with values from 0=best to 100=worst], Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant [high sensitivity C-reactive Protein milligram per liter (mg/L) (hsCRP)]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Less Than or Equal to (<=)10 [CDAI Low Disease Activity (LDA)] at Week 12
Query!
Assessment method [1]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
Query!
Assessment method [2]
0
0
Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0=least difficulty and 3=extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as reference for the comparison of active treatment arms.
Query!
Timepoint [2]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving 20% Improvement in ACR20 at Week 24 (Non-Inferiority Versus Tofacitinib)
Query!
Assessment method [3]
0
0
ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) [visual analogue scale (VAS) with values from 0=best to 100=worst], Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant [high sensitivity C-reactive Protein milligram per liter (mg/L) (hsCRP)].
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria (ACR50/70) at Week 24 and ACR 20/50/70 at and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [4]
0
0
ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20%/50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) [VAS with values from 0=best to 100=worst], Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ- DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant [high sensitivity C-reactive Protein mg/L (hsCRP)].
Query!
Timepoint [4]
0
0
Week 24 and Week 52
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving ACR20/50/70 at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [5]
0
0
ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20%/50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) [VAS with values from 0=best to 100=worst], Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ- DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant [high sensitivity C-reactive Protein mg/L (hsCRP)].
Query!
Timepoint [5]
0
0
Week 24 and Week 52
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [6]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10.
Query!
Timepoint [6]
0
0
Week 24 and Week 52
Query!
Secondary outcome [7]
0
0
Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [7]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10.
Query!
Timepoint [7]
0
0
Week 24 and Week 52
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 12
Query!
Assessment method [8]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score <=2.8. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [8]
0
0
Week 12
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [9]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score <=2.8.
Query!
Timepoint [9]
0
0
Week 24 and Week 52
Query!
Secondary outcome [10]
0
0
Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [10]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score <=2.8.
Query!
Timepoint [10]
0
0
Week 24 and Week 52
Query!
Secondary outcome [11]
0
0
Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria (ACR50/70) at Week 12
Query!
Assessment method [11]
0
0
ACR50/70 is calculated as a 50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) [VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [11]
0
0
Week 12
Query!
Secondary outcome [12]
0
0
Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <=3.2 (DAS28-CRP LDA) at Week 12
Query!
Assessment method [12]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [12]
0
0
Week 12
Query!
Secondary outcome [13]
0
0
Percentage of Participants Achieving DAS28 Erythrocyte Sedimentation Rate (ESR) <=3.2 (DAS28-ESR LDA) at Week 12
Query!
Assessment method [13]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter [mm]/hour[hr]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [13]
0
0
Week 12
Query!
Secondary outcome [14]
0
0
Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [14]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP<=3.2. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [14]
0
0
Week 24 and Week 52
Query!
Secondary outcome [15]
0
0
Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [15]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter [mm]/hour[hr]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [15]
0
0
Week 24 and Week 52
Query!
Secondary outcome [16]
0
0
Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [16]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP<=3.2. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [16]
0
0
Week 24 and Week 52
Query!
Secondary outcome [17]
0
0
Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [17]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter [mm]/hour[hr]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [17]
0
0
Week 24 and Week 52
Query!
Secondary outcome [18]
0
0
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 12
Query!
Assessment method [18]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-CRP less than (<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [18]
0
0
Week 12
Query!
Secondary outcome [19]
0
0
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 12
Query!
Assessment method [19]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [19]
0
0
Week 12
Query!
Secondary outcome [20]
0
0
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [20]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-CRP <2.6. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [20]
0
0
Week 24 and Week 52
Query!
Secondary outcome [21]
0
0
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [21]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [21]
0
0
Week 24 and Week 52
Query!
Secondary outcome [22]
0
0
Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [22]
0
0
The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-CRP <2.6. A negative change from baseline in DAS28-CRP indicates an improvement.
Query!
Timepoint [22]
0
0
Week 24 and Week 52
Query!
Secondary outcome [23]
0
0
Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [23]
0
0
The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Remission is achieved when DAS28-ESR <2.6. A negative change from baseline in DAS28-ESR indicates an improvement.
Query!
Timepoint [23]
0
0
Week 24 and Week 52
Query!
Secondary outcome [24]
0
0
Percentage of Participants Achieving a Good/Moderate (European League Against Rheumatism) EULAR Response at Week 12
Query!
Assessment method [24]
0
0
DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at given time point was defined based on the combination of current DAS28 score and improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; DAS28 <=3.2 and DAS28 decrease from Baseline (>1.2:good response), (>0.6 to <=1.2:moderate response) and (<=0.6:no response); DAS28 >3.2 to <=5.1 and DAS28 decrease from Baseline (>1.2:moderate response), (>0.6 to <=1.2:moderate response) and (<=0.6:no response) and DAS28 >5.1 and DAS28 decrease from Baseline (>1.2:moderate response), (>0.6 to <=1.2:no response) and (<=0.6:no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [24]
0
0
Week 12
Query!
Secondary outcome [25]
0
0
Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [25]
0
0
DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 <=3.2 and DAS28 decrease from Baseline (>1.2: good response), (>0.6 to <=1.2: moderate response) and (<=0.6: no response); if current DAS28 >3.2 to <=5.1 and DAS28 decrease from Baseline value (>1.2: moderate response), (>0.6 to <=1.2: moderate response) and (<=0.6: no response) and if current DAS28 >5.1 and DAS28 decrease from Baseline value (>1.2: moderate response), (>0.6 to <=1.2: no response) and (<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing.
Query!
Timepoint [25]
0
0
Week 24 and Week 52
Query!
Secondary outcome [26]
0
0
Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [26]
0
0
DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 <=3.2 and DAS28 decrease from Baseline (>1.2: good response), (>0.6 to <=1.2: moderate response) and (<=0.6: no response); if current DAS28 >3.2 to <=5.1 and DAS28 decrease from Baseline value (>1.2: moderate response), (>0.6 to <=1.2: moderate response) and (<=0.6: no response) and if current DAS28 >5.1 and DAS28 decrease from Baseline value (>1.2: moderate response), (>0.6 to <=1.2: no response) and (<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing.
Query!
Timepoint [26]
0
0
Week 24 and Week 52
Query!
Secondary outcome [27]
0
0
Number of Participants Achieving ACR/EULAR Remission at Week 12
Query!
Assessment method [27]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) <= 1, Swollen Joint Count 66 (SJC66) <= 1, high sensitivity C-reactive Protein (hsCRP) <= 1mg/dl and patient's global assessment of disease activity (PtGA) <= 10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [27]
0
0
Week 12
Query!
Secondary outcome [28]
0
0
Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [28]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) <= 1, Swollen Joint Count 66 (SJC66) <= 1, high sensitivity C-reactive Protein (hsCRP) <= 1mg/dl and patient's global assessment of disease activity (PtGA) <= 10.
Query!
Timepoint [28]
0
0
Week 24 and Week 52
Query!
Secondary outcome [29]
0
0
Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [29]
0
0
Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) <= 1, Swollen Joint Count 66 (SJC66) <= 1, high sensitivity C-reactive Protein (hsCRP) <= 1mg/dl and patient's global assessment of disease activity (PtGA) <= 10.
Query!
Timepoint [29]
0
0
Week 24 and Week 52
Query!
Secondary outcome [30]
0
0
Percentage of Participants Achieving no Radiographic Progression (Van Der Heijde Modified Total Sharp Scores (mTSS <= 0.5) at Week 12
Query!
Assessment method [30]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of <=0.5. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [30]
0
0
Week 12
Query!
Secondary outcome [31]
0
0
Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [31]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of <=0.5.
Query!
Timepoint [31]
0
0
Week 24 and Week 52
Query!
Secondary outcome [32]
0
0
Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [32]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of <=0.5.
Query!
Timepoint [32]
0
0
Week 24 and Week 52
Query!
Secondary outcome [33]
0
0
Change From Baseline in CDAI Total Score at Week 12
Query!
Assessment method [33]
0
0
Clinical Disease Activity Index (CDAI) total score is a composite score consisting of sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (PtGA and PhGA VAS with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [33]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [34]
0
0
Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [34]
0
0
CDAI total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [34]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [35]
0
0
Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [35]
0
0
CDAI total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score <=10. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [35]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [36]
0
0
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 12
Query!
Assessment method [36]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) [ESR in millimeter/hour (mm/hr)] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score range from 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [36]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [37]
0
0
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [37]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) [ESR in millimeter/hour (mm/hr)] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [37]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [38]
0
0
Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [38]
0
0
DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) [ESR in millimeter/hour (mm/hr)] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [38]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [39]
0
0
Change From Baseline in Van Der Heijde mTSS at Week 12
Query!
Assessment method [39]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [39]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [40]
0
0
Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [40]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [40]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [41]
0
0
Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [41]
0
0
Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [41]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [42]
0
0
Change From Baseline in HAQ-DI at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [42]
0
0
HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [42]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [43]
0
0
Change From Baseline in HAQ-DI at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [43]
0
0
HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [43]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [44]
0
0
Change From Baseline in Arthritis Pain VAS at Week 12
Query!
Assessment method [44]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [44]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [45]
0
0
Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [45]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [45]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [46]
0
0
Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [46]
0
0
For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at "0" (no pain) and "100" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [46]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [47]
0
0
Change From Baseline in Short Form (SF)-36 Physical Component Scores (PCS) at Week 12
Query!
Assessment method [47]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.
Query!
Timepoint [47]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [48]
0
0
Change From Baseline in SF-36 Mental Component Scores (MCS) at Week 12
Query!
Assessment method [48]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.
Query!
Timepoint [48]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [49]
0
0
Change From Baseline in SF-36 Domain Scores at Week 12
Query!
Assessment method [49]
0
0
Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (SF, vitality, MH, role-emotional) and PCS consists of 4 domains (PF, role-physical, BP and GH).The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring of SF-36.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits. CB=subtracting PD visit value from BV. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [49]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [50]
0
0
Change From Baseline in SF-36 PCS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [50]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.
Query!
Timepoint [50]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [51]
0
0
Change From Baseline in SF-36 MCS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [51]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.
Query!
Timepoint [51]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [52]
0
0
Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [52]
0
0
The Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.
Query!
Timepoint [52]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [53]
0
0
Change From Baseline in SF-36 PCS at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [53]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. PCS is primarily derived from 4 domains (PF,role-physical,BP,GH) representing overall physical health. Positive change from baseline, reported using T-score change, indicates improvement in overall physical health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [53]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [54]
0
0
Change From Baseline in SF-36 MCS at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [54]
0
0
SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health. Positive change from baseline, reported using T-score change, indicates improvement in overall mental health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [54]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [55]
0
0
Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [55]
0
0
Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning(PF), bodily pain(BP), role limitations due to physical and emotional problems, general health(GH), mental health(MH), social functioning(SF), vitality. The MCS consists of 4 domains (SF, vitality, MH, role-emotional) and PCS consists of 4 domains (PF, role-physical, BP, GH). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [55]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [56]
0
0
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12
Query!
Assessment method [56]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [56]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [57]
0
0
Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [57]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [57]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [58]
0
0
Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [58]
0
0
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.
Query!
Timepoint [58]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [59]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
Query!
Assessment method [59]
0
0
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death, cause life threatening events which requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity and birth defect or congenital anomaly. Protocol defined AESIs were included. Fifteen participants in Pooled placebo group who received active treatment of Tofacitinib from Week 4 instead of Week 12 as planned. They were pooled with the Tofacitinib arm in safety analysis.
Query!
Timepoint [59]
0
0
Up to Week 59
Query!
Secondary outcome [60]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) for Placebo Switched Arms
Query!
Assessment method [60]
0
0
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death, cause life threatening events which requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity and birth defect or congenital anomaly. Protocol defined AESIs were included.
Query!
Timepoint [60]
0
0
Up to Week 59
Query!
Secondary outcome [61]
0
0
Change From Baseline in White Blood Cell (WBC) Count at Week 12
Query!
Assessment method [61]
0
0
Blood samples were collected for the assessment of hematology parameter white blood cell count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [61]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [62]
0
0
Change From Baseline in WBC Count at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [62]
0
0
Blood samples were collected for the assessment of hematology parameter white blood cell count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [62]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [63]
0
0
Change From Baseline in WBC Count at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [63]
0
0
Blood samples were collected for the assessment of hematology parameter white blood cell count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [63]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [64]
0
0
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 12
Query!
Assessment method [64]
0
0
Blood samples were collected for the assessment of hematology parameters including platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [64]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [65]
0
0
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [65]
0
0
Blood samples were collected for the assessment of hematology parameters including platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [65]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [66]
0
0
Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [66]
0
0
Blood samples were collected for the assessment of hematology parameters including platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [66]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [67]
0
0
Change From Baseline in Hematology Parameter of Hemoglobin at Week 12
Query!
Assessment method [67]
0
0
Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [67]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [68]
0
0
Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [68]
0
0
Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [68]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [69]
0
0
Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [69]
0
0
Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [69]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [70]
0
0
Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma-Glutamyl Transpeptidase (GGT) at Week 12
Query!
Assessment method [70]
0
0
Blood samples were collected for the assessment of clinical chemistry parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP) and gamma-glutamyl transferase (GGT) levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [70]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [71]
0
0
Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [71]
0
0
Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [71]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [72]
0
0
Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [72]
0
0
Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [72]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [73]
0
0
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 12
Query!
Assessment method [73]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [73]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [74]
0
0
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [74]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [74]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [75]
0
0
Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [75]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [75]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [76]
0
0
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 12
Query!
Assessment method [76]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [76]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [77]
0
0
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [77]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [77]
0
0
Baseline (Day 1), Week 24 and Week 52
Query!
Secondary outcome [78]
0
0
Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Placebo Switched Arms
Query!
Assessment method [78]
0
0
Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [78]
0
0
Baseline (Week 12), Week 24 and Week 52
Query!
Secondary outcome [79]
0
0
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 12
Query!
Assessment method [79]
0
0
Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [79]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [80]
0
0
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [80]
0
0
Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [80]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [81]
0
0
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Placebo Switched Arms
Query!
Assessment method [81]
0
0
Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [81]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [82]
0
0
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [82]
0
0
Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [82]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [83]
0
0
Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Placebo Switched Arms
Query!
Assessment method [83]
0
0
Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [83]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [84]
0
0
Change From Baseline in Lipid Profile Parameter of Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein-cholesterol at Week 12
Query!
Assessment method [84]
0
0
Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [84]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [85]
0
0
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [85]
0
0
Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [85]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [86]
0
0
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 24 for Placebo Switched Arms
Query!
Assessment method [86]
0
0
Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [86]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [87]
0
0
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [87]
0
0
Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [87]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [88]
0
0
Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, High-density Lipoprotein-cholesterol at Week 52 for Placebo Switched Arms
Query!
Assessment method [88]
0
0
Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [88]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [89]
0
0
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 12
Query!
Assessment method [89]
0
0
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.
Query!
Timepoint [89]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [90]
0
0
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [90]
0
0
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [90]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [91]
0
0
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Placebo Switched Arms
Query!
Assessment method [91]
0
0
Blood samples were collected for the assessment of fasting lipid profile including triglycerides. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [91]
0
0
Baseline (Day 1) and Week 24
Query!
Secondary outcome [92]
0
0
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Treatment Arms Who Started Study Intervention From Day 1
Query!
Assessment method [92]
0
0
Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Query!
Timepoint [92]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [93]
0
0
Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Placebo Switched Arms
Query!
Assessment method [93]
0
0
Blood samples were collected for the assessment of fasting lipid profile including triglycerides. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.
Query!
Timepoint [93]
0
0
Baseline (Day 1) and Week 52
Query!
Secondary outcome [94]
0
0
Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) >=Grade 3 Hematological/Clinical Chemistry Abnormalities
Query!
Assessment method [94]
0
0
Number of participants with NCI-CTCAE >=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case >=Grade 3 shifts from Baseline. Fifteen participants in Pooled placebo group who received active treatment of Tofacitinib from Week 4 instead of Week 12 as planned. They were pooled with the Tofacitinib arm in safety analysis.
Query!
Timepoint [94]
0
0
Up to Week 59
Query!
Secondary outcome [95]
0
0
Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) >=Grade 3 Hematological/Clinical Chemistry Abnormalities for Placebo Switched Arms
Query!
Assessment method [95]
0
0
Number of participants with NCI-CTCAE >=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case >=Grade 3 shifts from Baseline.
Query!
Timepoint [95]
0
0
Up to Week 59
Query!
Secondary outcome [96]
0
0
Concentrations of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Autoantibody
Query!
Assessment method [96]
0
0
Concentrations of GM-CSF autoantibodies were determined.
Query!
Timepoint [96]
0
0
At baseline
Query!
Secondary outcome [97]
0
0
Number of Participants With Anti-GSK3196165 Antibodies
Query!
Assessment method [97]
0
0
Serum samples were collected for the determination of anti- GSK3196165 antibodies (ADA) using a validated electrochemiluminescence (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA.
Query!
Timepoint [97]
0
0
Up to Week 59
Query!
Eligibility
Key inclusion criteria
Key inclusion criteria
- >=18 years of age
- Has had RA for >=6 months and was not diagnosed before 16 years of age
- Has active disease, as defined by having both:*
- >=6/68 tender/painful joint count (TJC), and
- >=6/66 swollen joint count (SJC)
- Has at least 1 bone erosion present on hand/wrist or foot radiographs
- Has had an inadequate response to MTX, despite currently taking MTX 15-25 mg/week**
oral or injected
- If surgical treatment of a joint has been performed, that joint cannot be counted
in the TJC or SJC.
- A lower dose of 7.5 mg/week is acceptable if reduced for reasons of
intolerance to MTX or per local requirement.
Key exclusion criteria
- Has had any active and/or recurrent infections (excluding recurrent fungal infections
of the nail bed) or has required management of acute or chronic infections.
- Has received prior treatment with an antagonist of GM-CSF or its receptor or Janus
kinase (JAK) inhibitors (either experimental or approved)
- Has received prior treatment with a biologic Disease-modifying antirheumatic drug
(DMARD) which has been discontinued due to an inadequate response.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/05/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/08/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1537
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Dakota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Córdova
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa Fe
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Salta
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
San Juan
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Santiago Del Estero
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Ontario
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Anhui
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Jiangxi
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Jilin
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Sichuan
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Shanghai
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Brno
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Ostrava
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Praha 10
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 2
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 4 Nusle
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Praha 4
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Praha 5
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Uherske Hradiste
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Zlin
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Baja
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Balatonfured
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Budapest
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Kistarcsa
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Szekesfehervar
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szentes
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Székesfehérvár
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Veszprem
Query!
Country [46]
0
0
India
Query!
State/province [46]
0
0
Ahmedabad
Query!
Country [47]
0
0
India
Query!
State/province [47]
0
0
Banglore
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Belagavi
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Hubli
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Hyderabad
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Jaipur
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Kolkata
Query!
Country [53]
0
0
India
Query!
State/province [53]
0
0
Nagpur
Query!
Country [54]
0
0
India
Query!
State/province [54]
0
0
Nashik
Query!
Country [55]
0
0
India
Query!
State/province [55]
0
0
New Delhi
Query!
Country [56]
0
0
India
Query!
State/province [56]
0
0
Pimpri-Chinchwad
Query!
Country [57]
0
0
India
Query!
State/province [57]
0
0
Pune
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Rajkot
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Surat
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Vadodara
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Veneto
Query!
Country [62]
0
0
Latvia
Query!
State/province [62]
0
0
Adazi
Query!
Country [63]
0
0
Latvia
Query!
State/province [63]
0
0
Liepaja
Query!
Country [64]
0
0
Latvia
Query!
State/province [64]
0
0
Riga
Query!
Country [65]
0
0
Lithuania
Query!
State/province [65]
0
0
Kaunas
Query!
Country [66]
0
0
Lithuania
Query!
State/province [66]
0
0
Klaipeda
Query!
Country [67]
0
0
Lithuania
Query!
State/province [67]
0
0
Siauliai
Query!
Country [68]
0
0
Lithuania
Query!
State/province [68]
0
0
Vilnius
Query!
Country [69]
0
0
Malaysia
Query!
State/province [69]
0
0
Klang
Query!
Country [70]
0
0
Malaysia
Query!
State/province [70]
0
0
Kuala Lumpur
Query!
Country [71]
0
0
Malaysia
Query!
State/province [71]
0
0
Seremban, Negeri Sembilan
Query!
Country [72]
0
0
Malaysia
Query!
State/province [72]
0
0
Sibu
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Baja California Sur
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Guanajuato
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Jalisco
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Michoacán
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
Durango
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
Mexico
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Bialystok
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Bydgoszcz
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Czestochowa
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Gdansk
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Gdynia
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Katowice
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Kraków
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Lodz
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Lublin
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Nowa Sol
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Olsztyn
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Poznan
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Sochaczew
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Staszow
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Torun
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Warsaw
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Warszawa
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Wroclaw
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Zamosc
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Ekaterinburg
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Kemerovo
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Korolev
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Krasnoyarsk
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Moscow
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Novosibirsk
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Omsk
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Saint Petersburg
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Saint-Petersburg
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Saratov
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Smolensk
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Tomsk
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Tver
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Ulyanovsk
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Yaroslavl
Query!
Country [113]
0
0
Serbia
Query!
State/province [113]
0
0
Belgrade
Query!
Country [114]
0
0
South Africa
Query!
State/province [114]
0
0
Gauteng
Query!
Country [115]
0
0
South Africa
Query!
State/province [115]
0
0
KwaZulu- Natal
Query!
Country [116]
0
0
South Africa
Query!
State/province [116]
0
0
Bellville
Query!
Country [117]
0
0
South Africa
Query!
State/province [117]
0
0
Bloemfontein
Query!
Country [118]
0
0
South Africa
Query!
State/province [118]
0
0
Cape Town
Query!
Country [119]
0
0
South Africa
Query!
State/province [119]
0
0
Johannesburg
Query!
Country [120]
0
0
South Africa
Query!
State/province [120]
0
0
Kempton Park
Query!
Country [121]
0
0
South Africa
Query!
State/province [121]
0
0
Panorama, Cape Town
Query!
Country [122]
0
0
South Africa
Query!
State/province [122]
0
0
Pretoria
Query!
Country [123]
0
0
South Africa
Query!
State/province [123]
0
0
Somerset West
Query!
Country [124]
0
0
South Africa
Query!
State/province [124]
0
0
Stellenbosch
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
A Coruña
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Cordoba
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Santiago de Compostela
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Cherkasy
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Ivano-Frankivsk
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Kharkiv
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Kyiv
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Lutsk
Query!
Country [133]
0
0
Ukraine
Query!
State/province [133]
0
0
Lviv
Query!
Country [134]
0
0
Ukraine
Query!
State/province [134]
0
0
Odesa
Query!
Country [135]
0
0
Ukraine
Query!
State/province [135]
0
0
Odessa
Query!
Country [136]
0
0
Ukraine
Query!
State/province [136]
0
0
Poltava
Query!
Country [137]
0
0
Ukraine
Query!
State/province [137]
0
0
Vinnytsia
Query!
Country [138]
0
0
Ukraine
Query!
State/province [138]
0
0
Vinnytsya
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Zaporizhzhia
Query!
Country [140]
0
0
Ukraine
Query!
State/province [140]
0
0
Zaporizhzia
Query!
Country [141]
0
0
Ukraine
Query!
State/province [141]
0
0
Zhytomyr
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Essex
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Middlesex
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Warwickshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Iqvia Pty Ltd
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study [contRAst 1 (201790: NCT03980483)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to MTX. The study will consist of a screening phase of up to 6 weeks followed by a 52-week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with MTX. Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study [contRAst X (209564: NCT04333147)]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03980483
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/ct2/show/NCT03980483
Download to PDF